증기 및 과산화수소 생물학적 지표 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of steam and hydrogen peroxide biological indicators Market

The global steam and hydrogen peroxide biological indicators market was valued at USD 803.76 million in 2025 and is projected to grow to USD 865.02 million in 2026, reaching USD 1,644.03 million by 2034, exhibiting a CAGR of 8.36% from 2026 to 2034. North America led the global market in 2025 with a 34.90% share, driven by stringent infection control regulations, growing surgical volumes, and rapid adoption of sterilization monitoring protocols across healthcare and pharmaceutical sectors. The U.S. market is expected to reach USD 387.7 million by 2030, owing to rising surgical site infections and increased focus on sterilization in hospitals and dental clinics.

Market Overview and Product Insights

Biological indicators (BIs) provide a direct measure of sterilization effectiveness, ensuring reliable monitoring in processes using steam, hydrogen peroxide, ethylene oxide, and other sterilizing agents. The increasing emphasis on sterilization in healthcare facilities, pharmaceutical, biotechnology, and food industries drives market growth. Regulatory standards enforcing contamination prevention, combined with new product launches, have further accelerated the adoption of steam and hydrogen peroxide biological indicators.

Among product types, self-contained vials (SCBIs) hold the largest share due to their high reliability, ease of use, and rapid results. In 2026, the self-contained vials segment accounted for 67.33% of the market, valued at USD 582.4 million, driven by higher adoption in both developed and emerging healthcare markets. Spore strips hold the second-largest share due to their lower cost and suitability for smaller clinics and healthcare facilities. Spore-suspension indicators are also used but represent a smaller market segment.

Application Insights

By application, healthcare facilities dominate, accounting for 72.26% of the global market in 2026, valued at USD 625.1 million. The rise in hospital-acquired infections (HAIs) and the growing number of surgical procedures necessitate routine sterilization monitoring. Pharmaceutical and medical device companies hold the second-largest share, as stringent sterilization requirements prevent contamination and product recalls, emphasizing the importance of biological indicators in production workflows.

COVID-19 Impact

The COVID-19 pandemic accelerated demand for sterilization and disinfectant monitoring products. Hospitals, dental clinics, and pharmaceutical companies increased sterilization measures to avoid viral or bacterial HAIs. For example, 3M's medical solutions division reported a 25.9% revenue increase in 2020, reflecting the heightened demand for BIs during the pandemic. While post-pandemic growth normalized, the long-term demand remains strong due to ongoing surgical procedures and heightened infection control protocols.

Market Trends

The market is witnessing a shift toward rapid biological indicators, offering faster results than conventional products. Traditional indicators require 72-168 hours for incubation, whereas rapid BIs provide results in minutes. Regulatory approvals, such as the U.S. FDA approval of the Sterrad Velocity Biological Indicator in January 2020, support this trend, increasing adoption across pharmaceutical and medical device manufacturing.

Market Growth Factors

Rising surgical volumes, increasing prevalence of chronic diseases, and higher healthcare expenditure drive the need for sterile medical instruments. Globally, approximately 313 million surgeries are performed annually, according to the WHO. This creates significant demand for monitoring devices, including steam and hydrogen peroxide biological indicators. Product innovations, such as STERIS Spordex SCBI Ampoules launched in December 2020, further enhance market growth.

Restraining Factors

The adoption of BIs faces competition from alternate solutions like enzyme indicators, which offer faster results, ease of use, and lower costs. The high cost of BIs also limits widespread adoption, particularly in developing regions. For instance, the FDA approved Instant 20s Enzymatic Indicator by True Indicating LLC in December 2021, capable of monitoring steam sterilization processes rapidly, challenging traditional BIs.

Regional Insights

North America led in 2025 with USD 280.9 million, and the U.S. market is projected at USD 287.5 million by 2026. Europe shows steady growth, with the UK reaching USD 33.4 million and Germany USD 53.8 million by 2026, driven by geriatric populations and longer hospital stays. Asia Pacific is expected to witness the highest CAGR due to rapid expansion of pharmaceutical and medical device manufacturing, with Japan at USD 55.6 million, China at USD 72.3 million, and India at USD 41.8 million by 2026. Latin America and the Middle East & Africa account for smaller shares due to lower awareness.

Key Players and Industry Developments

Major players include 3M, STERIS, ASP, Getinge, Mesa Labs, Tuttnauer, Bioquell, and Terragene. Notable developments include:

• June 2022: 3M received approval for Attest Rapid Readout BI 1295 for vaporized hydrogen peroxide sterilization.
• March 2022: Tuttnauer acquired Prestige Medical Ltd. to expand distribution in selected countries.
• December 2021: Terragene partnered with Keir Surgical Ltd. to provide instant-read steam biological indicators.
• June 2021: STERIS acquired Cantel Medical LLC, adding Crosstex BI products to its portfolio.

Conclusion

The steam and hydrogen peroxide biological indicators market is set for robust growth, expanding from USD 803.76 million in 2025 to USD 1,644.03 million by 2034, driven by increasing surgical procedures, stringent sterilization regulations, and technological innovations in rapid biological indicators. Despite challenges from alternate products and high costs, the ongoing focus on patient safety, HAIs prevention, and sterilization efficiency ensures strong market potential across healthcare and pharmaceutical sectors globally.

Segmentation By Product Type, By Application, and By Geography

By Product Type * Self-contained Vials

• Spore Strips
• Spore-suspension

By Application * Pharmaceutical & Medical Device Companies

• Healthcare Facilities
• Others

By Geography

North America (By Product Type, By Application, and By Country)

• U.S.
• Canada
• Europe (By Product Type, By Application, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific (By Product Type, By Application, and By Country/Sub-region)
  • Japan
  • China
  • India
  • Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, By Application, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa (By Product Type, By Application, and By Country/Sub-region)
  • Turkey
  • Saudi Arabia
  • U.A.E.
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pricing, Key Players
• 4.2. Guidelines for Sterilization: Key Region
• 4.3. Key Mergers, Acquisitions, Partnerships, etc.
• 4.4. Impact of COVID-19 on the Market

5. Global Steam and Hydrogen Peroxide Biological Indicators Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Self-contained Vials
  • 5.1.2. Spore Strips
  • 5.1.3. Spore Suspension
• 5.2. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Application
  • 5.2.1. Pharmaceutical and Medical Device Companies
  • 5.2.2. Healthcare Facilities
  • 5.2.3. Others
• 5.3. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Steam and Hydrogen Peroxide Biological Indicators Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Self-contained Vials
  • 6.1.2. Spore Strips
  • 6.1.3. Spore Suspension
• 6.2. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Application
  • 6.2.1. Pharmaceutical and Medical Device Companies
  • 6.2.2. Healthcare Facilities
  • 6.2.3. Others
• 6.3. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Steam and Hydrogen Peroxide Biological Indicators Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Self-contained Vials
  • 7.1.2. Spore Strips
  • 7.1.3. Spore Suspension
• 7.2. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Application
  • 7.2.1. Pharmaceutical and Medical Device Companies
  • 7.2.2. Healthcare Facilities
  • 7.2.3. Others
• 7.3. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.3.1. Germany
  • 7.3.2. U.K.
  • 7.3.3. Italy
  • 7.3.4. France
  • 7.3.5. Russia
  • 7.3.6. Rest of Europe

8. Asia Pacific Steam and Hydrogen Peroxide Biological Indicators Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Self-contained Vials
  • 8.1.2. Spore Strips
  • 8.1.3. Spore Suspension
• 8.2. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Application
  • 8.2.1. Pharmaceutical and Medical Device Companies
  • 8.2.2. Healthcare Facilities
  • 8.2.3. Others
• 8.3. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. South Korea
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Steam and Hydrogen Peroxide Biological Indicators Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Self-contained Vials
  • 9.1.2. Spore Strips
  • 9.1.3. Spore Suspension
• 9.2. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Application
  • 9.2.1. Pharmaceutical and Medical Device Companies
  • 9.2.2. Healthcare Facilities
  • 9.2.3. Others
• 9.3. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Country/Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Argentina
  • 9.3.4. Rest of Latin America
• 9.4. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Product Type
  • 9.4.1. Self-contained Vials
  • 9.4.2. Spore Strips
  • 9.4.3. Spore Suspension
• 9.5. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Application
  • 9.5.1. Pharmaceutical and Medical Device Companies
  • 9.5.2. Healthcare Facilities
  • 9.5.3. Others
• 9.6. Market Revenue (USD million) and Volume (1,000 Units) Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Turkey
  • 9.6.2. Saudi Arabia
  • 9.6.3. United Arab Emirates (U.A.E)
  • 9.6.4. Rest of Middle East & Africa

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
  • 10.2.1. 3M
    • 10.2.1.1. Overview,
    • 10.2.1.2. Products,
    • 10.2.1.3. SWOT Analysis,
    • 10.2.1.4. Recent Developments,
    • 10.2.1.5. Strategies,
    • 10.2.1.6. financials (Based on Availability)
  • 10.2.2. Mesa Labs, Inc.
    • 10.2.2.1. Overview,
    • 10.2.2.2. Products,
    • 10.2.2.3. SWOT Analysis,
    • 10.2.2.4. Recent Developments,
    • 10.2.2.5. Strategies,
    • 10.2.2.6. financials (Based on Availability)
  • 10.2.3. Terragene
    • 10.2.3.1. Overview,
    • 10.2.3.2. Products,
    • 10.2.3.3. SWOT Analysis,
    • 10.2.3.4. Recent Developments,
    • 10.2.3.5. Strategies,
    • 10.2.3.6. financials (Based on Availability)
  • 10.2.4. Ecolab
    • 10.2.4.1. Overview,
    • 10.2.4.2. Products,
    • 10.2.4.3. SWOT Analysis,
    • 10.2.4.4. Recent Developments,
    • 10.2.4.5. Strategies,
    • 10.2.4.6. financials (Based on Availability)
  • 10.2.5. STERIS
    • 10.2.5.1. Overview,
    • 10.2.5.2. Products,
    • 10.2.5.3. SWOT Analysis,
    • 10.2.5.4. Recent Developments,
    • 10.2.5.5. Strategies,
    • 10.2.5.6. financials (Based on Availability)
  • 10.2.6. Liofilchem S.r.l.
    • 10.2.6.1. Overview,
    • 10.2.6.2. Products,
    • 10.2.6.3. SWOT Analysis,
    • 10.2.6.4. Recent Developments,
    • 10.2.6.5. Strategies,
    • 10.2.6.6. financials (Based on Availability)
  • 10.2.7. GKE-GmbH
    • 10.2.7.1. Overview,
    • 10.2.7.2. Products,
    • 10.2.7.3. SWOT Analysis,
    • 10.2.7.4. Recent Developments,
    • 10.2.7.5. Strategies,
    • 10.2.7.6. financials (Based on Availability)
  • 10.2.8. Getinge
    • 10.2.8.1. Overview,
    • 10.2.8.2. Products,
    • 10.2.8.3. SWOT Analysis,
    • 10.2.8.4. Recent Developments,
    • 10.2.8.5. Strategies,
    • 10.2.8.6. financials (Based on Availability)
  • 10.2.9. Tuttnauer
    • 10.2.9.1. Overview,
    • 10.2.9.2. Products,
    • 10.2.9.3. SWOT Analysis,
    • 10.2.9.4. Recent Developments,
    • 10.2.9.5. Strategies,
    • 10.2.9.6. financials (Based on Availability)
  • 10.2.10. Etigam bv
    • 10.2.10.1. Overview,
    • 10.2.10.2. Products,
    • 10.2.10.3. SWOT Analysis,
    • 10.2.10.4. Recent Developments,
    • 10.2.10.5. Strategies,
    • 10.2.10.6. financials (Based on Availability)
  • 10.2.11. Shanghai Fuze Medicine Equipment Co., Ltd.
    • 10.2.11.1. Overview,
    • 10.2.11.2. Products,
    • 10.2.11.3. SWOT Analysis,
    • 10.2.11.4. Recent Developments,
    • 10.2.11.5. Strategies,
    • 10.2.11.6. financials (Based on Availability)
  • 10.2.12. Zhejiang TAILIN Bioengineering Co., LTD
    • 10.2.12.1. Overview,
    • 10.2.12.2. Products,
    • 10.2.12.3. SWOT Analysis,
    • 10.2.12.4. Recent Developments,
    • 10.2.12.5. Strategies,
    • 10.2.12.6. financials (Based on Availability)
  • 10.2.13. SKAN AG
    • 10.2.13.1. Overview,
    • 10.2.13.2. Products,
    • 10.2.13.3. SWOT Analysis,
    • 10.2.13.4. Recent Developments,
    • 10.2.13.5. Strategies,
    • 10.2.13.6. financials (Based on Availability)